CD24: A Novel Target for Cancer Immunotherapy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Cluster of differentiation 24 (CD24) is a glycosylated cell adhesion protein found on immune and other cell types.
• Tumor CD24 expression correlates with oncogenic signaling pathway alterations.
• The CD24/Siglec-10 pathway is involved in tumor immune evasion, suppressing macrophage phagocytosis and natural killer (NK) cell cytotoxicity.

Purpose of the Study:

• To review current evidence on CD24 as a cancer immunotherapy target.
• To discuss future perspectives for CD24-targeted therapies.

Main Methods:

• Review of preclinical studies on CD24 blockade.
• Analysis of clinical trial data for anti-CD24 monoclonal antibodies.
• Evaluation of antibody-drug conjugates and CAR T cell therapy in preclinical settings.

Main Results:

• CD24 blockade demonstrates potential in preclinical cancer models.
• Monoclonal antibodies targeting CD24 show clinical safety and tolerability.
• Emerging therapies like antibody-drug conjugates and CAR T cells are being explored.

Conclusions:

• CD24 represents a promising target for cancer immunotherapy.
• Further research and clinical trials are warranted to optimize CD24-targeted treatment strategies.